Skip to Main Content

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Conditions

Pancreas

Phase 1B/2

What is the purpose of this trial?

A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

  • Trial with
    F. Hoffman-La Roche Ltd
  • Start Date
    09/26/2017
  • End Date
    11/02/2021
Trial Image

For more information about this study, contact:

Christina Wiess

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/25/2020
  • Study HIC
    #2000020737